- Details
- Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker. Dr. De Santis highlights the promising results of TAR-200, a novel gemcitabine intravesical system, which shows high complete...
|
- Details
- Dag Stormoen discusses research comparing genetic profiles of early and late-stage urothelial tract cancer. The study finds similar mutational profiles between muscle-invasive bladder cancer and heavily treated metastatic disease. Notably, a small cohort of advanced-stage patients showed unexpectedly long survival, with some living beyond five years. The research highlights the potential of geneti...
|
- Details
- David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and industry partners to develop and validate AI tools for cancer diagnosis and treatment prediction. Dr. McConkey emphasizes the importance of open access data, quality control, and rigorous validation in AI re...
|
- Details
- Roger Li discusses findings from a patient panel at the BCAN Think Tank, focusing on decision-making in BCG-unresponsive and muscle-invasive bladder cancer treatment. He emphasizes the emotional journey patients undergo and the importance of empowering them with information. Dr. Li highlights several patient stories, demonstrating diverse treatment choices ranging from bladder-sparing approaches t...
|
- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- Francesco Soria discusses a study validating the IBCG scoring system for intermediate-risk bladder cancer. He explains the heterogeneity of this risk group and the need for better stratification. Soria describes the IBCG model, which uses five risk factors to divide patients into three subgroups. The study validates this model using a large European cohort, showing significant differences in recur...
|
- Details
- Ashish Kamat interviews Felix Guerrero-Ramos about a European Urology Oncology review on novel treatments for non-muscle-invasive bladder cancer (NMIBC). Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC, focusing on intravesical and systemic approaches. He highlights FDA-approved treatments for BCG-unresponsive disease and ongoing trials for B...
|
- Details
- Sam Chang interviews Jason Brown about research on disparities in bladder cancer mortality between urban and rural settings from 2000 to 2020. Dr. Brown presents findings showing a significant decline in bladder cancer mortality in urban areas, particularly large metropolitan centers, while rates remain unchanged in rural areas. The study uses CDC data and Joinpoint Regression analysis to identify...
|
- Details
- In this discussion, Sam Chang interviews Saum Ghodoussipour about the role of circulating tumor DNA (ctDNA) as a biomarker in urothelial carcinoma. Dr. Ghodoussipour presents an overview of ctDNA's potential applications in various stages of bladder cancer, from non-muscle invasive to advanced disease. He highlights its utility in early detection, risk stratification, and monitoring treatment resp...
|
- Details
- Sam Chang host Mario de Angelis to discuss a study on trimodal therapy (TMT) for urothelial and non-urothelial invasive bladder cancer. Dr. De Angelis presents findings from a SEER database analysis of over 5,000 patients treated with TMT. The study reveals that TMT use has increased for organ-confined urothelial carcinoma but decreased for non-urothelial cases. For organ-confined disease, patient...
|
